Xigris had a 6% absolute benefit with a bleeding problemIt was a near split vote on the FDA approval with 3 of the YES votes tied in to receiving "stuff" from the Xigris story development. Something doesn't ADD up...we are safe, used on 150K + and show a 18% benefit on an undisclosed population with NO safety issue and many "side benefits", apparentlly bleeding to death is NOT a problem.....so "whad up Doc"???
Ronco and Dellinger cappucino video
Spectral has never, ever called Euphrates an "abdominal sepsis" trial
Interesting that when The video was shot, Dr.Ronco clearly stated that Euphrates was the first ever "theranostic trial" for ABDOMINAL Sepsis
Is this our 18% absolute benefit achievement?
Is the pre specified per protocol patient population just an intentional confusing tongue twister?
Why did it take 3 news releases to spit out the interim data when the FDA/DSMB size adjustment to 605 patients clearly suggested an 11 to 12% absolute efficacy?
Why did they change the trial and achieve FAR LESS on the pre specified per protocol pateint population?
Will the "three blind mice" act of 1937 come into play? We didn't know our efficacy was sliding faster than Ricky Henderson into 2nd base ( for you Breecher )??
Was switching the patient population at the April 2014 a MAJOR tactical error?
Tic Toc..I think we're being focked
The squire muses on